Fipamezole (JP-1730) is a potent ?2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease-Reference-Cited by-同舟云学术

Fipamezole (JP-1730) is a potent ?2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

Published:2003-07-24 Issue:8 Volume:18 Page:872-883
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Savola Juha-Matti,Hill Michael,Engstrom Mia,Merivuori Hannele,Wurster Siegfried,McGuire Steven G.,Fox Susan H.,Crossman Alan R.,Brotchie Jonathan M.

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference50 articles.

1. Levodopa-induced dyskinesia: Review, observations, and speculations

2. Strategies for Treating Patients with Advanced Parkinsonʼs Disease with Disastrous Fluctuations and Dyskinesias

3. Problems with Current Pharmacologic Treatment of Parkinson's Disease

4. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa

5. Long term outcome of unilateral pallidotomy: follow up of 15 patients for 3 years

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia;Neuropharmacology;2024-05

2. Comparative safety, pharmacokinetics, and off-target assessment of 1,1-bis(3′-indolyl)-1-(p-chlorophenyl) methane in mouse and dog: implications for therapeutic development;Toxicology Research;2024-03-01

3. Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study;Brain;2023-10-03

4. Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments;Current Drug Discovery Technologies;2023-09

5. Combined α2- and D2-receptor blockade activates noradrenergic and dopaminergic neurons, but extracellular dopamine in the prefrontal cortex is determined by uptake and release from noradrenergic terminals;Frontiers in Pharmacology;2023-08-23